Insider Trading Activity BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) – CEO Sold 5,000 shares of Stock

14

Insider Trading Activity For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Jean Jacques Bienaime , CEO of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) reportedly Sold 5,000 shares of the company’s stock at an average price of 91.73 for a total transaction amount of $458,650.00 SEC Form

Insider Trading History For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

  • On 8/22/2012 Mark Wood, VP, sold 2,665 with an average share price of $37.93 per share and the total transaction amounting to $101,083.45. View SEC Filing
  • On 9/4/2012 Henry J Fuchs, EVP, sold 5,000 with an average share price of $37.76 per share and the total transaction amounting to $188,800.00. View SEC Filing
  • On 11/12/2012 George Eric Davis, SVP, sold 99,075 with an average share price of $48.45 per share and the total transaction amounting to $4,800,183.75. View SEC Filing
  • On 12/27/2012 Jean Jacques Bienaime, CEO, sold 17,000 with an average share price of $48.37 per share and the total transaction amounting to $822,290.00. View SEC Filing
  • On 2/4/2013 Jean Jacques Bienaime, CEO, sold 2,000 with an average share price of $55.77 per share and the total transaction amounting to $111,540.00. View SEC Filing
  • On 2/22/2013 Mark Wood, VP, sold 3,103 with an average share price of $55.22 per share and the total transaction amounting to $171,347.66. View SEC Filing
  • On 3/4/2013 George Eric Davis, SVP, sold 4,000 with an average share price of $60.18 per share and the total transaction amounting to $240,720.00. View SEC Filing
  • Analyst Ratings For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
    These are 7 Hold Ratings, 13 Buy Ratings .
    The current consensus rating for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is Buy (Score: 2.65) with a consensus target price of $112.89 , a potential (25.44% upside)

    Analyst Ratings History For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

    • On 6/18/2015 Canaccord Genuity Boost Price Target of rating Buy with a price target of $115.00 to $150.00
    • On 8/4/2015 SunTrust Banks, Inc. Reiterated Rating Buy
    • On 10/13/2015 Raymond James Financial, Inc. Reiterated Rating Outperform with a price target of $157.00
    • On 1/15/2016 Bank of America Corp Reiterated Rating Buy with a price target of $165.00 to $135.00
    • On 6/20/2016 Oppenheimer Holdings Inc. Reiterated Rating Market Perform with a price target of $99.00
    • On 7/28/2016 William Blair Set Price Target of rating Buy with a price target of $116.00
    • On 8/5/2016 Stifel Nicolaus Boost Price Target of rating Buy with a price target of $107.00 to $113.00

    About BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
    BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company’s therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.

    Recent Trading Activity for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
    Shares of BioMarin Pharmaceutical Inc. closed the previous trading session at 90.13 up +0.14 0.16% with 1,192,983 shares trading hands.

    An ad to help with our costs